Leukemia Clinical Trials

Showing 5921-5940 of 10,987 trials

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT02403193

The purpose of this study is to determine the safety, tolerability, feasibility and preliminary efficacy of the administration of PBF-509 (Adenosine A2a receptor antagonist) as single agent or in combination with PDR001 (programmed cell death 1 receptor antibody (PD-1 Ab)) to NSCLC patients.

Non-small Cell Lung Cancer (NSCLC)

Palobiofarma SL92 participantsStarted Oct 2015

Tampa, Florida, United States

Not Yet RecruitingPhase 2

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

NCT05186506

This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive II-IIIA stage non-small cell lung cancer after surgical resection

ALK Fusion Protein ExpressionAdjuvant TherapyNon-Small Cell Lung Cancer

Sichuan University152 participantsStarted Jan 2022

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Related Searches

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Epidemiology of Pecan Nut Allergy

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer

Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)

PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)

FARE Peanut SLIT and Early Tolerance Induction

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib

De-prescribing Program to Evaluate Falls in Older Adults

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia

Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia

Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Epigenetic Regulation of Exercise Induced Asthma

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS